Effect of paclitaxel (taxol®) on ca 125 expression and release by ovarian cancer cell lines

Tumor Biology

Volumn 18, Issue 4, 1997, Pages 232-240

  Bonfrer, J M G ^a   Linders, T C ^a   Hageman, P C ^a   Hilkens, J G W ^a   Korse, C M ^a   Molthof, C F M ^b  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

CA 125 expression; Cremophor EL; Taxol

Indexed keywords

CA 125 ANTIGEN; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; FEMALE; IMMUNOHISTOCHEMISTRY; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL;

EID: 0030746422     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1159/000218036     Document Type: Article

References (24)

1. Thigpen JT: Chemotherapy of gynecologic cancer; in Perry MC (ed): The Chemotherapy Source Book, Baltimore, Williams and Wilkins, 1992, pp 1039-1067.
2. Hansen HH, Eisenhauer EA, Hansen M, Neijt JP, Piccart MJ, Sessa C, Thigpen JT: New cytostatic drugs in ovarian cancer, Ann Oncol 1993;4: 63-70.
3. Schiff PB, Fant J, Horwitz SB: Promotion of microtubule assembly in vitro by Taxol, Nature 1979:277: 665.
4. Rowinsky EK, Cazenave LA, Done-howcr RC: Taxol: A novel investigational antimicrotubule agent, J Natl Cancer Inst 1990;82:1247-1259.
5. Liebmann JE, Cook JA, Lipschultz C, Teague D, Fisher J, Mitchell JB: The influence of Cremophor EL on the cell cycle effects of paclita-xel (Taxol®) in human tumor cell lines, Cancer Chemother Pharmacol 1994;33:331-339.
6. Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer, N Engl J Med 1983;309:883-887.
7. Kcncmans P, Ycdcma CA, Bon GG, Mensdorff von-Pouilly S: CA 125 in gynecological pathology - a review, Eur J Obstct Gynecol Rcprod Biol 1993;49:115-124.
8. van dcr Burg MEL: Tumor marker CA 125, The clinical significance of the serum marker CA 125 in the management of patients with ovarian cancer; thesis, Amsterdam 1989: chapter 2:14.
9. Jacobs I, Bast RC Jr: The CA 125 tumour-associated antigen: A review of the literature, Hum Reprod 1989:4:1-12.
10. Tholander B, Lindgrcn A, Taube A: Immunohistochemical detection of CA 125 and carcinocmbryonic antigen in ovarian tumours in relation to corresponding preoperative serum levels, Int J Gynecol Cancer 1992;2: 263-270.
11. Flcuren GJ, Nap M, Aalders JG, Trimbos JB, De Bruijn HWA: Explanation of the limited correlation between tumor CA 125 content and serum CA 125 antigen levels in patients with ovarian tumors, Cancer 1987;60:2437-2442.
12. Bergmann JF, Bidart JM, George M, Beaugrand M, Levy VG, Bohuon C: Elevation of CA 125 in patients with benign and malignant ascites, Cancer 1987;59:213-217.
13. Tholander B, Taube A, Lindgren A: Pretreatment serum levels of CA 125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase in patients with ovarian carcinoma: Influence of histological type, grade of differentiation, and clinical stage of disease, Gynecol Oncol 1990:39:26- 33.
14. Hockman K, Huijskcns RVHP, Burger CW, Verheijen RHM, Pine-do HM, Vermorkcn JB: Günstig effect van paclitaxel (Taxol) bij pa-tienten met een platina voorbe-handeld ovariumcarcinoom, Ned Tijdschr Geneeskd 1995; 139:272- 278.
15. Mok SM, Wong K, Chan RKW, Lau CC, Tsao SW, Knapp RC, Berko-witz RS: Molecular cloning of differentially expressed genes in human epithelial ovarian cancer, Gynecol Oncol 1994;52:247-252.
16. Bonfrer JMG, Baan AW, Jansen E, Lentfer D, Kcncmans P: Technical evaluation of three second generation CA 125 assays, Eur J Clin Chcm Clin Biochem I994;32:201-207.
17. Willey TA, Bckos EJ, Gavcr RC, Duncan GF, Tay LK, Beijnen JH, Farmen RH: High-performance liquid chromatographic procedure for the quantitative determination of paclitaxel (Taxol®) in human plasma, J Chromatogr B Biomed Appl 1993;621:231-238.
18. Ishiwata I, Ishiwata C: CA 125 levels in the conditioned media of the gynecological tumor cell lines, Acta Obst Gynacc Jpn 1985;37:147-148.
19. Hills CA, Kelland LR, Abel G, Si-racky J, Wilson AP, Harrap K.R: Biological properties of the human ovarian carcinoma cell lines: Calibration in vitro against four platinum complexes, Br J Cancer 1989; 59:527-534.
20. Mobus V, Gcrharz CD, Press U, Moll R: Morphological, immunohis-tochcmical and biochemical characterization of 6 newly established human ovarian carcinoma cell lines, Int J Cancer 1992;52:76-84.
21. Ishiwata I, Ishiwata C, Soma M, No-zawa S, Ishikawa H: Characterization of newly established human ovarian carcinoma cell line - special reference of the effects of cis-plati-num on cellular proliferation and release of CA 125, Gynecol Oncol 1987;26:340-354.
22. Rustin GJS, van der Burg MEL, Berek JS: Tumour markers, Ann Oncol 1993;4:S71-S77.
23. Pearl ML, Yashar CM, Johnston CM, Reynolds RK, Roberts JA: Exponential regression of CA 125 during salvage treatment of ovarian cancer with taxol, Gynecol Oncol 1994;53:339-343.
24. Davelaar EM, Bonfrer JMG, Ver-straeten RA, Ten Bokkcl Huinink WW, Kenemans P: CA 125: A valid marker in ovarian carcinoma patients treated with Paclitaxel? Cancer 1996:78:118-127.